TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations
Authors: Kosmanopoulos Gage P , Donohue Jack K , Hoke Maya , Thomas Simone , Peyton Margo A , Vo Linh , Crawford Thomas O , Sadjadi Reza , Herrmann David N , Yum Sabrina W , Reilly Mary M , Scherer Steven S , Finkel Richard S , Lewis Richard A , Pareyson Davide , Pisciotta Chiara , Walk David , Shy Michael E , Sumner Charlotte J ,   Inherited Neuropathies Consortium - Rare Disease Clinical Research Network, Cavalca Eleonora , Crivellari Luca , Day John , Laura Matilde , Magri Stefania , Moroni Isabella , Mukherjee-Clavin Bipasha , Pagliano Emanuela , Rossor Alex , Saveri Paola , Schirinzi Giulia , Skorupinska Mariola , Sowden Janet , Taroni Franco , Wood Elizabeth , McCray Brett A 
Published: June 2024

Abstract
Dominant missense mutations of the calcium-permeable cation channel TRPV4 cause Charcot-Marie-Tooth disease (CMT) type 2C and two forms of distal spinal muscular atrophy. These conditions are collectively referred to as TRPV4-related neuromuscular disease and share features of motor greater than sensory dysfunction and frequent vocal fold weakness. Pathogenic variants lead to gain of ion channel function that can be rescued by TRPV4 antagonists in cellular and animal models. As small molecule TRPV4 antagonists have proven safe in trials for other disease indications, channel inhibition is a promising therapeutic strategy for TRPV4 patients. However, the current knowledge of the clinical features and natural history of TRPV4-related neuromuscular disease is insufficient to enable rational clinical trial design. To address these issues, we developed a TRPV4 patient database and administered a TRPV4-specific patient questionnaire.
Here, we report demographic and clinical information, including CMT Examination Scores (CMTES), from 68 patients with known pathogenic TRPV4 variants, 40 of whom also completed the TRPV4 patient questionnaire. TRPV4 patients showed a bimodal age of onset, with the largest peak occurring in the first 2 years of life. Compared to CMT type 1A (CMT1A) patients, TRPV4 patients showed distinct symptoms and signs, manifesting more ambulatory difficulties and more frequent involvement of proximal arm and leg muscles. Although patients reported fewer sensory symptoms, sensory dysfunction was often detected clinically. Many patients were affected by vocal fold weakness (55%) and shortness of breath (55%), and 11% required ventilatory support. Skeletal abnormalities were common, including scoliosis (64%), arthrogryposis (33%) and foot deformities. Strikingly, patients with infantile onset of disease showed less sensory involvement and less progression of symptoms.
These results highlight distinctive clinical features in TRPV4 patients, including motor-predominant disease, proximal arm and leg weakness, severe ambulatory difficulties, vocal fold weakness, respiratory dysfunction and skeletal involvement. In addition, patients with infantile onset of disease appeared to have a distinct phenotype with less apparent disease progression based on CMTES. These collective observations indicate that clinical trial design for TRPV4-related neuromuscular disease should include outcome measures that reliably capture non-length dependent motor dysfunction, vocal fold weakness and respiratory disease.